Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 1, Pages 1–2
http://dx.doi.org/10.1155/2013/321071
Editorial

Biomarkers for Psychiatric Disorders: Where Are We Standing?

1Research Group of Proteomics, Department of Psychiatry and Psychotherapy, Ludwig Maximilians University (LMU), Nussbaumstraße 7, 80336 Munich, Germany
2Research group of Proteomics and Biomarkers, Max Planck Institute of Psychiatry, Munich, Germany
3Laboratorio de Neurociências (LIM-27), Instituto de Psiquaitria, Faculdade de Medicina da Universidade de São Paulo, SP, São Paulo, Brazil

Received 16 April 2013; Accepted 18 April 2013

Copyright © 2013 Daniel Martins-de-Souza. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Gonzalez-Pinto, M. Gutierrez, F. Mosquera et al., “First episode in bipolar disorder: misdiagnosis and psychotic symptoms,” Journal of Affective Disorders, vol. 50, no. 1, pp. 41–44, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. J. C. Wakefield, “Misdiagnosing normality: psychiatry's failure to address the problem of false positive diagnoses of mental disorder in a changing professional environment,” Journal of Mental Health, vol. 19, no. 4, pp. 337–351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Schwarz, R. Izmailov, M. Spain et al., “Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia,” Biomarker Insights, vol. 2010, no. 5, pp. 39–47, 2010. View at Google Scholar · View at Scopus
  4. D. Martins-de-Souza, “Translational strategies to schizophrenia from a proteomic perspective,” Translational Neuroscience, vol. 3, no. 3, pp. 300–302, 2012. View at Google Scholar
  5. A. G. Cardno and I. I. Gottesman, “Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics,” American Journal of Medical Genetics, vol. 97, no. 1, pp. 12–17, 2000. View at Google Scholar
  6. O. D. Howes, C. McDonald, M. Cannon, L. Arseneault, J. Boydell, and R. M. Murray, “Pathways to schizophrenia: the impact of environmental factors,” International Journal of Neuropsychopharmacology, vol. 7, supplement 1, pp. S7–S13, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Martins-de-Souza, “Is the word ‘biomarker’ being properly used by proteomics research in neuroscience?” The European Archives of Psychiatry and Clinical Neuroscience, vol. 260, no. 7, pp. 561–562, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Bahn, E. Schwarz, L. W. Harris, D. Martins-de-Souza et al., “Biomarker blood tests for diagnosis and management of mental disorders: focus on schizophrenia,” Revista de Psiquiatria Clínica, vol. 40, no. 1, article 7, 2013. View at Google Scholar